NEW YORK (360Dx) – Roka Bioscience said after the close of the market on Thursday that its first quarter revenues grew 25 percent year over year.

For the three months ended March 31, the company posted $2.0 million in revenues, up from $1.6 million. Growth was driven by a 26 percent increase in the number of pathogen detection tests sold, Roka Bio said, as the number of Atlas molecular diagnostics instruments placed with customers grew to 54 in Q1 2017 compared to 44 in the year-ago quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.